Company
Business
Stem Cell Therapy
Organoid
CDMO Business
PR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Technology Export Possibility Planning Engineer
27
2025.05
On May 26, 2025, Financial News published an article discussing the potential for technology export by Kangstem Biotech.
On May 26, 2025, Financial News published an article discussing the potential for technology export by Kangstem Biotech.
The article highlighted the global licensing potential and expectations surrounding “OSCA,” a treatment aimed at fundamentally addressing osteoarthritis, as well as the company’s organoid platform, which is gaining attention in the market as an alternative to animal testing.
OSCA has secured structural improvement data through its Phase 1 clinical trial, including improvements in symptoms and joint function, as well as regeneration of cartilage and subchondral bone. Based on these results, it is currently undergoing Phase 2a clinical trials. Notably, OSCA has drawn significant market attention for demonstrating strong efficacy with a single intra-articular injection—without the need for surgery.
Kangstem’s skin organoids replicate the structure and function of normal human skin, including not only the epidermis and dermis but also hair follicles, sebaceous glands, melanocytes, nerve cells, subcutaneous fat tissue, blood vessels, and immune cells—achieving a level nearly quivalent to actual human skin.
Additionally, the organoids have been used to induce atopic dermatitis and test existing treatments, confirming their potential as a model for evaluating the efficacy of new drug candidates.
The head of Kangstem Biotech’s Business Development Division stated that the company is currently in discussions with major global pharmaceutical companies, leveraging the outstanding technology and unique competitiveness of both OSCA and its skin organoid platform. In particular, the company aims to conclude a technology licensing agreement for OSCA during its ongoing Phase 2a trial and anticipates that a technology transfer deal for the skin organoids could take place in the near future.